2025
Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial
O’Malley S, Miranda R, Book S, Chun T, Liss T, Malcolm R, Muvvala S, Padovano H, Schacht J, Blackburn B, Diamond I, Ransom J, Ryan M, Falk D, Litten R. Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial. Alcohol And Alcoholism 2025, 60: agaf001. PMID: 39829301, PMCID: PMC11744046, DOI: 10.1093/alcalc/agaf001.Peer-Reviewed Original ResearchAlcohol use disorderAldehyde dehydrogenase 2 inhibitorUse disorderTreat alcohol use disorderCue reactivity sessionsCue-elicited cravingCue-induced cravingHuman laboratory studiesTreatment-seeking adultsAlcohol use disorder pharmacotherapiesAldehyde dehydrogenase 2Multisite clinical trialDose to placeboWeeks of medicationEffect size estimatesReactivation sessionDrinking outcomesGroup differencesCravingMeasured 1 weekEffect sizeCohen's dDouble-blindPreliminary effectivenessAlcohol consumption
2024
Availability of Medications for Opioid Use Disorder in US Psychiatric Hospitals
Cohen S, Beetham T, Fiellin D, Muvvala S. Availability of Medications for Opioid Use Disorder in US Psychiatric Hospitals. JAMA Network Open 2024, 7: e2444679. PMID: 39535800, PMCID: PMC11561693, DOI: 10.1001/jamanetworkopen.2024.44679.Peer-Reviewed Original ResearchThe Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review
Jegede O, De Aquino J, Hsaio C, Caldwell E, Funaro M, Petrakis I, Muvvala S. The Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review. Journal Of Addiction Medicine 2024, 18: 499-510. PMID: 39356620, PMCID: PMC11449257, DOI: 10.1097/adm.0000000000001356.Peer-Reviewed Original ResearchNonmedical opioid useOpioid use disorderOpioid useWithdrawal symptomsTreatment outcomesSymptoms prior to treatmentUse disorderRisk of precipitated withdrawalLow-dose buprenorphineSynthetic opioidsPotency synthetic opioidsConclusions Current evidencePrecipitated withdrawalRisk of overdoseDosing strategiesPharmacological interactionsClinical significanceDecreased riskWeb of ScienceOpioidInclusion criteriaCurrent evidenceClinical implicationsMOUDPain
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply